港股異動丨和鉑醫藥-B大漲近9% 新藥HBM1020獲准在美啟動臨牀試驗
格隆匯1月16日丨和鉑醫藥-B(2142.HK)大幅拉昇漲約9%,現報3.86港元創6個月新高價,月內累計升幅近40%,總市值29.6億港元。公司日前宣佈,其全球首創靶向B7H7(即HHLA2)全人源單克隆抗體HBM1020獲得美國食品藥品監管局(FDA)的新藥研究申請許可(IND),將在美國啟動相關臨牀試驗。該試驗是一項開放標籤的多中心I期研究,用以評估HBM1020在晚期實體瘤患者中的安全性、耐受性、藥代動力學和抗腫瘤活性。值得一提是,HBM1020是全球首個正式獲批進入臨牀階段的抗B7H7單克隆抗體。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.